APOLLO HOSPITALS ENTERPRISE LIMITED

CIN : L85110TN1979PLC008035

August 12, 2026

The Secretary, Bombay Stock Exchange Ltd (BSE) Phiroze Jheejheebhoy Towers, Dalal Street, Mumbai – 400 001. **Scrip Code – 508869** **ISIN INE437A01024**	The Secretary, National Stock Exchange, Exchange Plaza, 5th Floor Plot No.C/1, 'G' Block Bandra – Kurla Complex Bandra (E) Mumbai – 400 051. **Scrip Code– APOLLOHOSP** **ISIN INE437A01024**

Dear Sir/Madam,

Sub: Outcome of the Board Meeting

This has reference to our letters dated 25th June and 16th July 2026, regarding the captioned subject. The Board at its meeting held today transacted the following items of business.

Financial Results

1. Approved the Unaudited financial results (both standalone and consolidated) of the Company for the three months ended 30th June 2026, which have been subjected to Limited Review by the Statutory Auditors of the Company – as **Annexure A**.

2. A Copy of the Limited Review Report of the Statutory Auditors for the corresponding period is attached herewith.

3. The unaudited financial results will also be published in the newspapers, in the format prescribed under Regulation 47 of the Listing Regulations.

4. The said documents are being posted on the website of the Company i.e., www.apollohospitals.com.

APOLLO HOSPITALS ENTERPRISE LIMITED CHENNAI

IS/ISO 9001 : 2000

Regd. Office :
19, Bishop Gardens,
Raja Annamalaipuram,
Chennai - 600 028.

General Office :
"Ali Towers" III Floor,
#55, Greams Road,
Chennai - 600 006.

Tel : 044 - 28290956 / 3896 / 6681
Telefax : 044 - 2829 0956
Email : investor.relations@apollohospitals.com
Website : www.apollohospitals.com

Appointment of M/s Price Waterhouse Chartered Accountants LLP, Chartered Accountants as the Statutory Auditors of the Company for a term of five years, commencing from the conclusion of the 46th AGM (to be held in the year 2027)

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that based on the recommendation of the Audit Committee, the Board of Directors at its Meeting held today i.e. August 12, 2026, has approved the appointment of M/s Price Waterhouse Chartered Accountants LLP, Chartered Accountants, (ICAI Firm Registration No.: 012754N/N500016), as Statutory Auditors of the Company for a term of five years, commencing from the conclusion of the 46th AGM (to be held in the year 2027) until the conclusion of the 51st AGM (to be held in the year 2032), subject to Shareholders' approval and other statutory requirements (including auditor independence requirements for the Company and its subsidiaries) and in accordance with the laws and regulations in India and other jurisdictions as applicable.

It is hereby submitted that M/s Deloitte Haskins & Sells LLP, Chartered Accountants (ICAI Firm Registration No. 117366W/W-100018), the current Statutory Auditor, will continue to undertake the audit of the Company until the conclusion of the 46th Annual General Meeting to be held in the year 2027.

The details as required under Regulation 30 of the SEBI Listing Regulations read with SEBI Master Circular No. SEBI/HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 ('SEBI Circular'), are enclosed in **Annexure B** below.

Transfer of Undertaking by Apollo Healthco Limited to its wholly owned subsidiary

Pursuant to Regulation 30 of the Listing Regulations, we wish to inform you that the board of directors of Apollo Hospitals Enterprise Limited ("Company") has taken note of the proposed transfer by Apollo Healthco Limited ("AHL"), a material subsidiary of the Company, of its undertaking pertaining to the business of procurement and wholesale distribution of fast-

APOLLO HOSPITALS ENTERPRISE LIMITED CHENNAI

moving consumer goods, wellness and personal care products (including over-the-counter and non-prescription consumer healthcare products) and other related ancillary products categorised as fast moving consumer goods ("Transferred Undertaking"), as a going concern on a 'slump sale basis', to Apollo Consumer Products Limited ("ACPL"), a wholly-owned subsidiary of AHL, subject to approval of its shareholders.

The details as required under Regulation 30 of the SEBI Listing Regulations read with SEBI Master Circular No. SEBI/HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 ('SEBI Circular'), are enclosed in **Annexure C**

Grant of Stock Options under Apollo ESOP Plan 2024

In pursuance to the approval obtained from the Members at the Annual General Meeting held on 30th August 2024, for issue of 21,56,770 equity shares of Rs. 5/- each, the Company had obtained in -principle approval from the stock exchanges for listing of a maximum of 21,56,770 equity shares of Rs. 5/- each to be allotted to the employees of the Company under the Apollo Hospitals Enterprise Limited – Employee Stock Option Plan 2024 (Apollo ESOP 2024) of the Company. Today, based on the recommendations of the Nomination and Remuneration Committee, the Board has considered and approved the grant of additional stock options and RSUs aggregating to and representing a total of 46,798 equity shares of INR 5/- each to the new employees of the Company under the Apollo Hospitals Enterprise Limited Employee Stock Option Plan 2024 (Apollo ESOP 2024).

The details as required under Regulation 30 of the SEBI Listing Regulations read with SEBI Master Circular No. SEBI/HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 ('SEBI Circular'), are enclosed in **Annexure D**

APOLLO HOSPITALS ENTERPRISE LIMITED CHENNAI

Regd. Office :
19, Bishop Gardens,
Raja Annamalaipuram,
Chennai - 600 028.

General Office :
"Ali Towers" III Floor,
#55, Greams Road,
Chennai - 600 006.

Tel : 044 - 28290956 / 3896 / 6681
Telefax : 044 - 2829 0956
Email : investor.relations@apollohospitals.com
Website : www.apollohospitals.com

We request you to take the aforesaid on record, and to treat the same as compliance with the applicable provisions of the Listing Regulations.

The Board Meeting commenced today at 4.35 p.m and concluded at 7.00 p.m.

The above information is also being made available on the Company's website at www.apollohospitals.com

Thanking you

Yours faithfully,
For Apollo Hospitals Enterprise Limited

SM Krishnan
Sr. Vice President – Finance
and Company Secretary

SANKARAN ARAYANAN MUTHU KRISHNAN Digitally signed by SANKARANARAYANAN MUTHU KRISHNAN Date: 2026.08.12 19:32:44 +05'30'

Annexure A

Apollo Hospitals Enterprise Limited

Corporate Identity Number : L85110TN1979PLC008035

Regd. Office : No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai - 28, Tamil Nadu

Tel No. 44-28290956 , Fax+ 91-44-282 90956, Email : investor.relations@apollohospitals.com

Website: www.apollohospitals.com

Statement of standalone unaudited financial results for the three months ended June 30, 2026

(Rs. in Million)

	Particulars	Three months ended 30/06/2026	Preceeding three months ended 31/03/2026	Corresponding three months ended 30/06/2025	Previous year ended 31/03/2026
		Unaudited	Refer Note 2	Unaudited	Audited
1	**Income**				
	(a) Revenue from operations	26,561	24,385	21,679	93,262
	(b) Other income	471	903	325	3,718
	Total income	**27,032**	**25,288**	**22,004**	**96,980**
2	**Expenses**				
	(a) Cost of materials consumed	6,671	6,062	5,897	24,188
	(b) Employee benefits expense	4,583	4,412	4,037	16,862
	(c) Finance costs	683	634	588	2,417
	(d) Depreciation and amortisation expenses	1,343	1,280	1,232	5,004
	(e) Other expenses	8,745	7,956	6,284	28,932
	Total expenses	**22,025**	**20,344**	**18,038**	**77,403**
3	**Profit before tax and exceptional items (1) - (2)**	**5,007**	**4,944**	**3,966**	**19,577**
4	Exceptional item (Refer note 8)	-	-		(114)
5	**Profit before tax (3) + (4)**	**5,007**	**4,944**	**3,966**	**19,463**
6	**Tax expense**				
	Current tax	1,246	1,382	893	4,573
	Deferred tax	(91)	(262)	4	(36)
7	**Profit after tax for the period / year (5) - (6)**	**3,852**	**3,824**	**3,069**	**14,926**
8	**Other comprehensive income/(loss)**				
	Items that will not be reclassified to profit or loss				
	(a) Remeasurement gains/(losses) on defined benefit plans	45	(78)	76	(142)
	(b) Net change in fair value of investments in equity instruments measured at fair value	-	(10)	-	(10)
	(c) Income tax relating to items that will not be reclassified to profit or loss	(11)	20	(19)	36
	Total other comprehensive income/ (loss)	34	(68)	57	(116)
9	**Total comprehensive income for the period/year (7) + (8)**	**3,886**	**3,756**	**3,126**	**14,810**
10	Paid-up equity share capital (Face value Rs.5/- per share)				719
11	Reserves (excluding revaluation reserves)				98,913
12	**Earnings per equity share ('EPS') of Rs.5/- each**				
	Basic EPS for the period/year (Rs.)	*26.79	*26.59	*21.35	103.81
	Diluted EPS for the period/year (Rs.)	*26.78	*26.56	*21.35	103.74
13	**Additional Information :-**				
	Earnings before finance costs, tax, depreciation and amortization, other income, exceptional items (EBITDA) (refer foot note)	6,562	5,955	5,461	23,280

*Not annualised

Foot note:

1 The Company has presented EBITDA additionally as part of standalone financial results.

For APOLLO HOSPITALS ENTERPRISE LTD

SUNEETA REDDY
Managing Director

Apollo Hospitals Enterprise Limited
Corporate Identity Number : L85110TN1979PLC008035
Regd. Office : No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai - 28, Tamil Nadu
Tel No. 44-28290956 , Fax+ 91-44-282 90956, Email : investor.relations@apollohospitals.com
Website: www.apollohospitals.com

NOTES TO THE UNAUDITED STANDALONE FINANCIAL RESULTS:

1. The standalone unaudited financial information of **Apollo Hospitals Enterprise Limited** ("the Company") for the three months ended June 30, 2026 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meetings held on August 11, 2026 and August 12, 2026 respectively. The statutory auditors, Deloitte Haskins & Sells LLP have expressed an unmodified review conclusion on the unaudited financial results for the three months ended June 30, 2026.

2. The standalone financial results for the three months ended March 31, 2026 are the balancing figures between the audited standalone figures of the full financial year and the unaudited year to date standalone figures for the nine months ended December 31, 2025, which were subject to limited review.

3. The standalone unaudited financial results has been prepared in accordance with the Indian Accounting Standards ("Ind AS") as prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder and in terms of Regulation 33 of SEBI (Listing Obligation and Disclosure requirements) Regulations, 2015.

4. The Company's business activity primarily falls within a single reportable business segment namely "Healthcare Services" and operates primarily in India and accordingly does not have any additional disclosure to be made under Ind As 108- "Segment Reporting".

5. The Board at its meeting held on 30th June 2025, subject to necessary approvals considered and approved a Composite Scheme of Arrangement amongst, the Company (AHEL), Apollo Healthco Limited ("Transferor Company 1" or "AHL") – Keimed Private Limited ("Transferor Company 2"), and Apollo Healthtech Limited ("Resultant Company") and their respective shareholders and creditors ("Scheme"), in accordance with the provisions of Sections 230–232 and other applicable provisions of the Companies Act, 2013, the SEBI (LODR) Regulations, 2015 read with SEBI Master Circular dated June 20, 2023 (SEBI/HO/CFD/POD-2/P/CIR/2023/93), and other applicable rules, regulations, and circulars issued by regulatory authorities.

   The Scheme inter alia provides for demerger of identified business undertaking (as defined in the scheme) primarily representing the Omni channel pharmacy distribution business and digital health platform business of the Company into the Resultant Company; the amalgamation of "Transferor Company 1" with and into the Resultant Company; the amalgamation of "Transferor Company 2" with and into the Resultant Company; and the consequent listing of the equity shares of the Resultant Company on the National Stock Exchange of India Limited and Bombay Stock Exchange Limited and admission to trading.

For APOLLO HOSPITALS ENTERPRISE LTD

SUNEETA REDDY
Managing Director

National Stock Exchange of India Limited and BSE Limited have issued letters dated December 23 and December 24, 2025 respectively, under regulation 37 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Based on the directions of the Hon'ble Company Law Tribunal, meetings of the Secured Creditors, Unsecured Creditors and the Equity Shareholders of the Company were convened on 24th June, 2026 with requisite approvals being obtained for implementation of the Scheme and status being updated to the Company Law Tribunal . Subsequent to the receipt of such approvals, the Company has filed a petition before the National Company Law Tribunal seeking sanction of the scheme.

6. The Board also approved a Business Framework Agreement dated June 30, 2025, between AHEL and AHL to establish a framework of rights and restrictions pursuant to which each party shall: (i) independently pursue its respective businesses; and (ii) collaborate and cooperate with the other for mutual benefit. Upon effectiveness of the Scheme, the rights and obligations of AHL under this agreement will be binding on the Resultant Company.

7. The Board of Directors in their meeting held on May 20, 2026, approved the proposal for merger of Apollo Hospitals North Limited, a wholly owned subsidiary with the Company.

8. On November 21, 2025, the Government of India notified provisions of the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020 and the Occupational Safety, Health and Working Conditions Code, 2020, ('Labour Codes') Which consolidate twenty nine existing labour laws into a unified framework governing employee benefits during employment and post-employment.

   The Company has assessed the financial implications of these changes, which has resulted in increase in gratuity liability arising out of past service cost and increase in leave liability by Rs. 114 million for the year ended March 31,2026. Considering the materiality and regulatory driven non-recurring nature of this impact, the Company has presented the same as Exceptional item in the Statement, The Company continues to monitor the finalisation Of Central and State Rules, as well as Government clarifications on other aspects of the Labour Codes, and will incorporate appropriate accounting treatment based on these developments as required.

9. The aforesaid unaudited financial results are also available on the Company's website (www.apollohospitals.com).

For **APOLLO HOSPITALS ENTERPRISE LIMITED**

Place: Chennai
Date: August 12, 2026

Dr. Prathap C Reddy
Executive Chairman

For APOLLO HOSPITALS ENTERPRISE LTD

Suneeta Reddy

SUNEETA REDDY
Managing Director

Deloitte
Haskins & Sells LLP

Chartered Accountants
ASV Ramana Tower
52, Venkatnarayana Road
T. Nagar
Chennai-600 017
Tamil Nadu, India

Tel: +91 44 6688 5000

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF
APOLLO HOPSITALS ENTERPRISE LIMITED

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **Apollo Hospitals Enterprise Limited** ("the Company"), for the three months ended June 30, 2026 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **DELOITTE HASKINS & SELLS LLP**
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)

DELOITTE HASKINS & SELLS LLP CHENNAI CHARTERED ACCOUNTANTS

Nachiappan Subramanian
Partner
Membership No. 218727
UDIN:26218727UEKEWO2234

Place: Chennai
Date: August 12, 2026

Apollo Hospitals Enterprise Limited

Corporate Identity Number : L85110TN1979PLC008035
Regd. Office : No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai - 28, Tamil Nadu
Tel No. 44-28290956 , Fax+ 91-44-282 90956, Email : investor.relations@apollohospitals.com
Website: www.apollohospitals.com

Statement of consolidated unaudited financial results for the three months ended June 30, 2026

(Rs. in Million)

Particulars	Three months ended 30/06/2026	Preceding three months ended 31/03/2026	Corresponding three months ended 30/06/2025	Previous year ended 31/03/2026
	Unaudited	Refer Note 2	Unaudited	Audited
1 **Income**				
(a) Revenue from operations	70,435	66,055	58,421	2,52,285
(b) Other income	488	439	402	1,916
Total Income (a + b)	**70,923**	**66,494**	**58,823**	**2,54,201**
2 **Expenses**				
(a) Cost of materials consumed	8,290	7,774	7,401	30,408
(b) Purchases of stock-in-trade	27,678	26,131	23,155	1,00,564
(c) Changes in inventories of stock-in-trade	3	115	(80)	(216)
(d) Employee benefits expense	7,958	7,720	7,126	30,003
(e) Finance costs	1,204	1,191	1,083	4,496
(f) Depreciation and amortisation expense	2,351	2,244	2,147	8,761
(g) Other expenses	15,585	14,205	12,300	53,833
Total expenses	**63,069**	**59,380**	**53,132**	**2,27,849**
3 **Profit before share of profit/(loss) in associates / joint ventures and exceptional items (1) - (2)**	**7,854**	**7,114**	**5,691**	**26,352**
4 Share of profit/(loss) of associates /joint ventures	134	101	136	449
5 **Profit before tax and exceptional items (3) + (4)**	**7,988**	**7,215**	**5,827**	**26,801**
6 Exceptional item (Refer note 8)	-	-	-	(192)
7 **Profit before tax (5) + (6)**	**7,988**	**7,215**	**5,827**	**26,609**
8 **Tax expenses**				
Current tax	2,103	1,960	1,248	6,293
Deferred tax	(219)	(258)	169	289
9 **Profit after tax for the period/year (7) - (8)**	**6,104**	**5,513**	**4,410**	**20,027**
10 **Other Comprehensive Income**				
Items that will not be reclassified to profit or loss				
Remeasurement gains / (losses) on defined benefit plan	40	(76)	61	(116)
Equity instruments through other comprehensive income	-	(10)	-	735
Income tax relating to items that will not be reclassified to profit or loss	(2)	31	(2)	(64)
Items that will be reclassified to profit or loss	-			
Exchange differences in translating the financial statements of foreign operations	1	14	(0)	29
Total other comprehensive income/ (loss)	**39**	**(41)**	**59**	**584**
11 **Total comprehensive income for the period/year (9) + (10)**	**6,143**	**5,472**	**4,469**	**20,611**
Profit for the period/ year attributable to:				
Owners of the parent	5,807	5,293	4,328	19,417
Non-controlling interest	297	220	82	610
Other comprehensive income/ (loss) for the period/ year attributable to:				
Owners of the parent	40	(47)	60	577
Non-controlling interest	(1)	6	(1)	7
Total comprehensive income for the period/ year attributable to:				
Owners of the parent	5,847	5,246	4,388	19,994
Non-controlling interest	296	226	81	617
12 Paid-up equity share capital (Face value Rs.5/- per share)				719
Reserves (excluding revaluation reserves)				94,004
13 **Earnings per equity share ('EPS') of Rs.5/- each**				
Basic EPS for the period/year (Rs.)	*40.39	*36.82	*30.10	135.04
Diluted EPS for the period/year (Rs.)	*40.37	*36.76	*30.10	134.94

*Not annualised

For APOLLO HOSPITALS ENTERPRISE LTD

Suneeta Reddy

SUNEETA REDDY
Managing Director

Apollo Hospitals Enterprise Limited

Corporate Identity Number : L85110TN1979PLC008035
Regd. Office : No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai - 28, Tamil Nadu
Tel No. 44-28290956 , Fax+ 91-44-282 90956, Email : investor.relations@apollohospitals.com
Website: www.apollohospitals.com

Consolidated Segment wise revenue, results, segment assets and segment liabilities

(Rs. in Million)

Particulars	Three months ended 30/06/2026	Preceding three months ended 31/03/2026	Corresponding three months ended 30/06/2025	Previous year ended 31/03/2026
	Unaudited	Refer Note 2	Unaudited	Audited
1.Segment revenue				
a) Healthcare services	36,195	33,337	29,738	1,27,501
b) Retail health and diagnostics	4,995	4,895	4,351	18,653
c) Digital health and pharmacy distribution	29,770	28,482	24,719	1,08,081
d) Others	13	13	13	52
SUB - TOTAL	**70,973**	**66,727**	**58,821**	**2,54,287**
Less : Intersegmental revenue	538	672	400	2,002
Revenue from operations	**70,435**	**66,055**	**58,421**	**2,52,285**
2. Segment results				
a) Healthcare services	6,859	6,146	5,619	24,303
b) Retail health and diagnostics	227	399	71	723
c) Digital health and pharmacy distribution	1,523	1,357	692	3,987
d) Others	(39)	(36)	(10)	(81)
SUB - TOTAL	**8,570**	**7,866**	**6,372**	**28,932**
Less: (i) Finance cost	(1,204)	(1,191)	(1,083)	(4,496)
Add: (ii) Other un-allocable income, (net of expenditure)	488	439	402	1,916
Add: (iii) Share of profit/(loss) of associates / joint ventures	134	101	136	449
Add: (iv) Exceptional item (Refer note 8)	-	-	-	(192)
Profit before tax	**7,988**	**7,215**	**5,827**	**26,609**
3. Capital employed				
a) Healthcare services *				
Segment assets	1,49,864	1,44,862	1,29,519	1,44,862
Segment liabilities	(42,018)	(39,357)	(42,263)	(39,357)
b) Retail health and diagnostics				
Segment assets	15,166	14,732	14,094	14,732
Segment liabilities	(11,591)	(11,436)	(11,572)	(11,436)
c) Digital health and pharmacy distribution				
Segment assets	34,971	33,181	30,614	33,181
Segment liabilities	(10,082)	(9,466)	(10,041)	(9,466)
d) Others				
Segment assets	249	257	273	257
Segment liabilities	(185)	(183)	(178)	(183)
e) Unallocated				
Segment assets	31,860	28,937	38,814	28,937
Segment liabilities	(62,072)	(61,782)	(57,994)	(61,782)
Total	**1,06,162**	**99,745**	**91,266**	**99,745**
* Includes Capital employed in various hospital projects under construction	12,052	10,324	8,423	10,324

For APOLLO HOSPITALS ENTERPRISE LTD

SUNEETA REDDY
Managing Director

Apollo Hospitals Enterprise Limited

Corporate Identity Number : L85110TN1979PLC008035
Regd. Office : No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai - 28, Tamil Nadu
Tel No. 44-28290956 , Fax+ 91-44-282 90956, Email : investor.relations@apollohospitals.com
Website: www.apollohospitals.com

NOTES TO THE STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS:

1. The consolidated unaudited financial information of **Apollo Hospitals Enterprise Limited** ("the Company") for the three months ended June 30, 2026 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meetings held on August 11, 2026 and August 12, 2026 respectively. The statutory auditors, Deloitte Haskins & Sells LLP have expressed an unmodified review conclusion on the consolidated unaudited financial results for the three months ended June 30, 2026.

2. The consolidated financial results for the three months ended March 31, 2026 are the balancing figures between the audited consolidated figures of the full financial year and the unaudited year to date consolidated figures for the nine months ended December 31, 2025, which were subject to limited review.

3. The consolidated unaudited financial results have been prepared in accordance with the Indian Accounting Standards ("Ind AS") as prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder and in terms of Regulation 33 of SEBI (Listing Obligation and Disclosure requirements) Regulations, 2015.

4. The Board at its meeting held on 30th June 2025, subject to necessary approvals considered and approved a Composite Scheme of Arrangement amongst, the Company (AHEL), Apollo Healthco Limited ("Transferor Company 1" or "AHL") – Keimed Private Limited ("Transferor Company 2"), and Apollo Healthtech Limited ("Resultant Company") and their respective shareholders and creditors ("Scheme"), in accordance with the provisions of Sections 230–232 and other applicable provisions of the Companies Act, 2013, the SEBI (LODR) Regulations, 2015 read with SEBI Master Circular dated June 20, 2023 (SEBI/HO/CFD/POD-2/P/CIR/2023/93), and other applicable rules, regulations, and circulars issued by regulatory authorities.

   The Scheme inter alia provides for demerger of identified business undertaking (as defined in the scheme) primarily representing the Omni channel pharmacy distribution business and digital health platform business of the Company into the Resultant Company; the amalgamation of "Transferor Company 1" with and into the Resultant Company; the amalgamation of "Transferor Company 2" with and into the Resultant Company; and the consequent listing of the equity shares of the Resultant Company on the National Stock Exchange of India Limited and Bombay Stock Exchange Limited and admission to trading.

   National Stock Exchange of India Limited and BSE Limited have issued letters dated December 23 and December 24, 2025 respectively, under regulation 37 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Based on the directions of the Hon'ble Company Law Tribunal, meetings of the Secured Creditors, Unsecured Creditors and the Equity Shareholders of the Company were convened on 24th June, 2026 with requisite approvals being obtained for implementation of the Scheme and status being updated to the Company Law Tribunal . Subsequent to the receipt of such approvals, the Company has filed a petition before the National Company Law Tribunal seeking sanction of the scheme.

For APOLLO HOSPITALS ENTERPRISE LTD

SUNEETA REDDY
Managing Director

5. The Board also approved a Business Framework Agreement dated June 30, 2025, between AHEL and AHL to establish a framework of rights and restrictions pursuant to which each party shall: (i) independently pursue its respective businesses; and (ii) collaborate and cooperate with the other for mutual benefit. Upon effectiveness of the Scheme, the rights and obligations of AHL under this agreement will be binding on the Resultant Company.

6. The Board of Directors in their meeting held on May 20, 2026, approved the proposal for merger of Apollo Hospitals North Limited, a wholly owned subsidiary with the Company.

7. Apollo Health and Lifestyle Limited ("AHLL"), a wholly owned subsidiary of the Company, has announced plans to combine with Kids Clinic India Limited, which operates under the brand name "Cloudnine", to create one of India's largest maternity and fertility care platform in India. As part of this arrangement, AHLL will divest its stake in its subsidiaries, namely Apollo Specialty Hospitals Private Limited and Apollo Fertility Centre Private Limited, to Kids Clinic India Limited at an enterprise value of approximately Rs.15,500 million, comprising a combination of cash consideration and an equity stake of approximately 9.9% in Kids Clinic India Limited. The transaction has been approved by the Board of Directors of the Company at its meeting held on May 20, 2026 and is subject to receipt of regulatory approvals, including approval of the Competition Commission of India (CCI).

8. On November 21, 2025, the Government of India notified provisions or the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020 and the Occupational Safety, Health and Working Conditions Code, 2020, ('Labour Codes') which consolidate twenty nine existing labour laws into a unified framework governing employee benefits during employment and post-employment.

   The Group has assessed the financial implications Of these changes, which has resulted in increase in gratuity liability arising out of past service cost and increase in leave liability by Rs 192 million for the year ended March 31,2026. Considering the materiality and regulatory- driven non-recurring nature of this impact, the Group has presented the same as Exceptional Items in the statement. The Group continues to monitor the finalisation of Central and State Rules, as well as Government clarifications on other aspects of the Labour Codes, and will incorporate appropriate accounting treatment based on these developments as required.

9. The Honourable High Court of Karnataka on October 8, 2021 had set aside the order of the Revenue Department, State of Karnataka ("Revenue Department") initiated earlier against a subsidiary alleging non-compliance with certain conditions associated with the allotment of land to the subsidiary and had directed the Revenue Department to reconsider and dispose the matter. The Revenue Department had issued a show cause notice dated February 9, 2022 seeking explanations as to why the original order should be withdrawn, for which the subsidiary had filed a detailed response explaining that there were no violations of the conditions relating to the allotment of land.

For APOLLO HOSPITALS ENTERPRISE LTD

Suneeta Reddy

SUNEETA REDDY
Managing Director

Apollo Hospitals Enterprise Limited

Corporate Identity Number : L85110TN1979PLC008035
Regd. Office : No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai - 28, Tamil Nadu
Tel No. 44-28290956 , Fax+ 91-44-282 90956, Email : investor.relations@apollohospitals.com
Website: www.apollohospitals.com

During the previous year ended 31st March 2026, the Revenue Department passed an order dated February 13, 2026 cancelling the grant order, alleging that the land had been alienated by the subsidiary on account of share purchase by its holding company. The subsidiary has challenged the said order before the Honourable High Court of Karnataka. The Honourable High Court of Karnataka has granted an interim stay on April 10, 2026 against the cancellation order and has directed the Revenue Department to file its objections.

Based on external legal opinions received, including opinions supporting that transfer of shares does not constitute transfer, alienation or sub-lease of immovable property owned by the subsidiary, the group believes that it has adequate grounds to demonstrate compliance with the applicable conditions of the land grant. Accordingly, the subsidiary has adequate grounds to demonstrate compliance with applicable conditions and therefore is of the opinion that the matter would be settled in its favour.

10. The aforesaid unaudited financial results are also available on the Company's website (www.apollohospitals.com).

For **APOLLO HOSPITALS ENTERPRISE LIMITED**

Place: Chennai
Date: August 12, 2026

Dr. Prathap C Reddy
Executive Chairman

For APOLLO HOSPITALS ENTERPRISE LTD
SUNEETA REDDY
Managing Director

Deloitte Haskins & Sells LLP

Chartered Accountants
ASV Ramana Tower
52, Venkatnarayana Road
T. Nagar
Chennai-600 017
Tamil Nadu, India

Tel: +91 44 6688 5000

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF
APOLLO HOSPITALS ENTERPRISE LIMITED

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **Apollo Hospitals Enterprise Limited** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net profit after tax and total comprehensive income of its associates and joint ventures for the three months ended 30th June 2026 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:

Name of the Company	Relationship
Apollo Hospitals Enterprise Limited (AHEL)	Parent
Apollo Home Healthcare Limited (AHHL)	Subsidiary
AB Medical Centres Limited	Subsidiary
Samudra Health Care Enterprises Limited	Subsidiary
Imperial Hospitals & Research Centre Limited (IHRCL)	Subsidiary

DELOITTE HASKINS & SELLS LLP
CHENNAI
CHARTERED ACCOUNTANTS

Name of the Company	Relationship
Belenus Champion Hospitals Limited (w.e.f 2 February 2026)	Subsidiary of IHRCL
Apollo Hospitals (UK) Limited	Subsidiary
Apollo Health and Lifestyle Limited (AHLL)	Subsidiary
Alliance Dental Care Limited	Subsidiary of AHLL
Apollo Dialysis Private Limited	Subsidiary of AHLL
Apollo Sugar Clinics Limited	Subsidiary of AHLL
Apollo Speciality Hospitals Limited	Subsidiary of AHLL
AHLL Diagnostics Limited	Subsidiary of AHLL
AHLL Risk Management Private Limited	Subsidiary of AHLL
Care Diagnostics Private Limited (w.e.f. 1 February 2026)	Subsidiary of AHLL
Apollo Dialysis Philippines Inc.	Subsidiary of AHLL
Apollo Fertility Centre Private Limited (Formerly known as Surya Fertility Centre Private Limited)	Stepdown Subsidiary of AHLL
Apollo Spectra Centres Private Limited (Formerly known as Kshema Healthcare Private Limited)	Stepdown Subsidiary of AHLL
Apollo Cradle and Children Hospital Private Limited	Stepdown Subsidiary of AHLL
Apollo Nellore Hospital Limited	Subsidiary
Sapien Bio-sciences Private Limited	Subsidiary
Apollo Hospitals International Limited (AHIL)	Subsidiary
Apollo CVHF Limited	Subsidiary of AHIL
Apollo Lavasa Health Corporation Limited	Subsidiary
Apollo Rajshree Hospital Private Limited (ARHPL)	Subsidiary
Sobhagya Hospital and Research Centre Private Limited	Subsidiary of ARHPL
Future Parking Private Limited	Subsidiary
Total Health	Subsidiary
Apollo Hospitals Singapore Pte Limited	Subsidiary
Assam Hospitals Limited (Assam)	Subsidiary
Asclepius Hospitals and Healthcare Private Limited	Subsidiary of Assam
Apollomedics International Lifesciences Limited	Subsidiary
Apollo Multi Specialty Hospitals Limited (AMSHL)	Subsidiary
Apollo HealthCo Limited (AHL)	Subsidiary
Apollo 24/7 Insurance Services Limited	Subsidiary of AHL
Apollo Consumer Products Limited (w.e.f 31 March 2026)	Subsidiary of AHL
Apollo Medical Private Limited (AMPL)	Associate of AHL
Apollo Pharmacies Limited	Subsidiary of AMPL
Apollo Pharmalogistics Private Limited	Subsidiary of AMPL
Apollo Pharma Products Pvt Limited	Subsidiary of AMPL
Apollo Hospitals North Limited	Subsidiary
Kerala First Health Services Private Limited (KFHS)	Subsidiary
Baalayam Healthcare Private Limited	Subsidiary of KFHS
Health Axis Private Limited (HAPL)	Subsidiary

DELOITTE HASKINS & SELLS LLP CHENNAI CHARTERED ACCOUNTANTS

Deloitte
Haskins & Sells LLP

Name of the Company	Relationship
Apollo Health Axis Inc (w.e.f 12 November 2025)	Subsidiary of HAPL
Opstronomy Health Technologies Private Limited (w.e.f. 17 June 2026)	Subsidiary of HAPL
Nexify Health Private Limited	Joint venture of HAPL
Apollo Hospitals Jammu and Kashmir Limited	Subsidiary
Apollo Hospitals Worli LLP	Subsidiary
Apollo Healthtech Limited (w.e.f. 10 June 2025)	Subsidiary
Apollo Gleneagles PET-CT Private Limited (w.e.f 30 September 2025)	Subsidiary
Family Health Plan Insurance (TPA) Limited	Associate
Indraprastha Medical Corporation Limited	Associate
Stemcyte India Therapeutics Private Limited	Associate
ApoKos Rehab Private Limited	Joint venture

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. We draw attention to Note 9 to the Statement in respect of proceedings initiated against the subsidiary, Imperial Hospitals and Research Centre Limited, by the Government of Karnataka. Our conclusion on the Statement is not modified in respect of this matter.

7. We did not review the interim financial results of 29 subsidiaries included in the consolidated unaudited financial results, whose interim financial results reflect total revenues of Rs. 5,619 million for the three months ended June 30, 2026, total net profit after tax of Rs. 706 million for the three months ended June 30, 2026 and total comprehensive income of Rs. 706 million for the three months ended June 30, 2026, as considered in the Statement. The consolidated unaudited financial results also includes the Group's share of profit after tax of Rs. 129 million for the three months ended June 30, 2026 and total comprehensive income of Rs. 134 million for the three months ended June 30, 2026, as considered in the Statement, in respect of 1 joint ventures and 5 associates (including 3 subsidiaries of 1 associate), whose interim financial results have not been reviewed by us.

DELOITTE HASKINS & SELLS LLP
CHENNAI
CHARTERED ACCOUNTANTS

These interim financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, joint ventures and associates, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of these matters.

8. The consolidated unaudited financial results includes the interim financial results of 8 subsidiaries which have not been reviewed by their auditors, whose interim financial results reflect total revenue of Rs. 46 million for the three months ended June 30, 2026, total profit after tax of Rs. 11 million for the three months ended June 30, 2026 and total comprehensive profit of Rs. 10 million for the three months ended June 30, 2026 as considered in the Statement. The consolidated unaudited financial results also includes the Group's share of loss after tax of Rs. 1 million for the three months ended June 30, 2026 and total comprehensive loss of Rs. 1 million for the three months ended June 30, 2026 as considered in the Statement, in respect of 2 associate, based on its interim financial results which have not been reviewed by its auditors. According to the information and explanations given to us by the Management, these interim financial results are not material to the Group.

   Our conclusion on the Statement is not modified in respect of our reliance on the interim financial results certified by the Management.

For **DELOITTE HASKINS & SELLS LLP**
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)

DELOITTE HASKINS & SELLS LLP CHENNAI CHARTERED ACCOUNTANTS

Nachiappan Subramanian
Partner
Membership No. 218727
UDIN: 26218727MZGKGO6296

Place: Chennai
Date: August 12, 2026

PRESS RELEASE

August 12, 2026

Apollo Hospitals Q1FY27 Results

Apollo Hospitals Announces Strong Q1FY27 Performance and Key Strategic Milestones

Q1 FY27 Consolidated Revenue grew 21% YoY to Rs. 7,043 Crore.

Q1 FY27 Consolidated EBITDA grew 28% YoY to Rs. 1,092 Crore.

Q1FY27 Consolidated PAT at Rs. 581 Crore.

- Healthcare Services Revenue grew 22% YoY. EBITDA Stood at Rs. 862 Crore.
- Apollo Health and Lifestyle Limited Revenue grew 15% at Rs. 499 Crore.
- Apollo HealthCo Reported Revenue of Rs. 2,977 Crore and EBITDA of Rs. 171 Crore.
- Revenue growth driven by Robust volume increase in Congo T Specialties and high Complexity Clinical work.
- Apollo Hospitals Continues Capacity growth momentum with the launch of 180 bed hospital in Sarjapur, Bangalore. The Gurugram facility remains on track for commissioning in Q3FY27.
- Apollo Hospitals also announces the expansion of its existing hospital facilities in Indore & Guwahati by 148 beds and addition of 4 new hospitals in Indore, Dwarka, Delhi Proton Centre and Ranchi totaling to 1200 beds, with these additions, Apollo Hospitals now has plans to add over 5800 total beds (4700 census beds) over the next 5 years.
- The International Patient Services division continued to witness increasing traction with a YOY revenue growth of 26%, reinforcing Apollo's position as a preferred global healthcare destination.

Key Clinical Highlights

- Indraprastha Apollo Hospitals, New Delhi: Performed India's first leadless pacemaker implantation across a prosthetic tricuspid valve, avoiding high-risk repeat open-heart surgery.
- Indraprastha Apollo Hospitals, New Delhi: Performed India's first reported robotic Whipple procedure in a patient with intestinal nonrotation and periampullary cancer.
- Apollo Hospitals, Kolkata: Performed India's first native transcatheter tricuspid valve replacement in a patient with inoperable tricuspid regurgitation.
- Apollo BGS Hospitals, Mysuru: Successfully performed laparoscopic adrenalectomy for a hormonally active adrenal myelolipoma, improving blood pressure control.
- Apollo Hospitals, Ahmedabad: Successfully performed complex pulmonary endarterectomy for high-risk chronic thromboembolic pulmonary hypertension despite severe thrombocytopenia.

Dr. Prathap C. Reddy, Founder & Chairman, Apollo Hospitals Group, said:

"Q1 FY27 marks a strong start to the year, building on the momentum of FY26. Consolidated revenue grew 21% year-on-year to ₹7,043 crore, supported by strong-based performance across Healthcare Services, Diagnostics and Retail Health, and Digital Health and Pharmacy. The performance reflects the strength of our integrated model and the continued trust that patients and their families place in Apollo.

I am particularly encouraged by this performance at a time when Indian healthcare is undergoing an important transition. India has made remarkable progress in expanding access to quality healthcare over the past four decades. Institutions like Apollo have both the opportunity and the responsibility to contribute to that transformation. The rising burden of non-communicable diseases and growing need for specialised care require us to move beyond episodic treatment towards a model that connects prevention, early diagnosis, advanced intervention and long-term care. Apollo's integrated healthcare ecosystem is well placed to support this shift. Above all, these results reflect the enduring trust that patients and their families place in us. That trust remains our greatest responsibility.

During the quarter, we continued to expand access to advanced care with the commissioning of our hospitals in Sarjapur Bangalore in Q1FY27, Apollo has now plans to add over 5800 total beds over the next 5 years.

Apollo HealthCo continued to pursue profitable and sustainable growth by strengthening its omnichannel pharmacy network and digital healthcare delivery. Together with our diagnostics and retail health businesses, these platforms are making healthcare more convenient, enabling earlier intervention and helping people engage with their health more consistently.

International patient demand remained steady, supported by our engagement with governments, embassies and healthcare partners. The continued confidence of patients from around the world reflects the strength of India's clinical expertise and reinforces its potential to become a leading global destination for high-quality healthcare.

As we look ahead, we will remain focused on clinical excellence and patient safety, preventive and patient-centric care, disciplined expansion and prudent capital allocation. Growth is meaningful only when it allows us to touch more lives. Apollo will remain steadfast in its founding purpose, to bring world-class healthcare, delivered with compassion, within the reach of every family and to help build a healthier India."

Q1FY27 FINANCIAL PERFORMANCE

Consolidated Q1 FY27 Performance

- Revenue at Rs. 7,043 Crore vs Rs.5,842 Crore in Q1 FY26; growth of 21% YoY
- EBITDA at Rs. 1,092 Crore vs Rs. 852 Crore in Q1 FY26. This is after Apollo 24/7 cost Rs. 91 Crore in the quarter vs Rs. 121 Crore in Q1 FY26.
- Reported PAT at Rs. 581 Crore vs Rs. 433 Crore in Q1 FY26
- Diluted EPS of Rs. 40.36 per share in Q1 FY27 (not annualized)

Healthcare Services Q1 FY27 Performance

- Revenue at Rs. 3,567 Crore vs Rs. 2,935 Crore in Q1 FY26; growth of 22% YoY
- EBITDA at Rs. 862 Crore vs Rs. 718 Crore in Q1 FY26; growth of 20% YoY; margin at 24%
- PAT at Rs. 480 Crore vs Rs. 384 Crore in Q1 FY26; growth of 25% YoY

Apollo Health and Lifestyle Limited Q1 FY27 Performance

- Revenue at Rs. 499 Crore vs Rs. 435 Crore in Q1 FY26; growth of 15% YoY
- EBITDA at Rs. 59 Crore vs Rs. 40 Crore in Q1 FY26; margin at 12%
- PAT loss at Rs. 1 Crore vs PAT loss of Rs. 8 Crore in Q1 FY26

Apollo HealthCo Q1 FY27 Performance

- Revenue at Rs. 2,977 Crore vs Rs. 2,472 Crore in Q1 FY26; growth of 20% YoY
- EBITDA at Rs. 171 Crore vs Rs. 94 Crore in Q1 FY26; margin at 6%
- PAT at Rs. 101 Crore vs Rs. 57 Crore in Q1 FY26

SEGMENT-WISE PERFORMANCE UPDATE

Healthcare Services (Hospitals)

As on June 30, 2026, Apollo Hospitals had 8,352 operating beds across the network, excluding AHLL and managed beds, with overall occupancy at 70% versus 65% in Q1 FY26. Healthcare Services revenue increased 22% YoY to ₹3,567 crore, while EBITDA (post Ind AS 116) stood at ₹862 crore, up 20% YoY.

The New hospitals with a combined operating capacity of 380 beds in Financial District, Sonarpur, Pune and Delhi Oncology was commissioned in Q4FY26 and Sarjapur launched in Q1FY27 reported an EBITDA loss of Rs.38 Cr in Q1FY27.

Regional performance:

Tamil Nadu: Revenue grew by 16%, IP volumes grew by 13%, and ARPP grew by 5% to Rs.2,13,309.
Overall occupancy was 1,404 beds (70%) compared with 1,261 beds (62%) in Q1 FY26.

AP-Telangana: Revenue grew by 31%, IP volumes grew by 25%, and ARPP grew by 7% to Rs.1,94,605. Overall occupancy was 948 beds (67%) compared with 813 beds (63%) in Q1 FY26.

Karnataka: Revenue grew by 21%, IP volumes grew by 10%, and ARPP grew by 12% to Rs. 1,96,748. Overall occupancy was 578 beds (70%) compared with 534 beds (69%) in Q1 FY26

Eastern: Revenue grew by 20%, IP volumes grew by 12%, and ARPP grew by 9% to Rs. 1,58,952. Overall occupancy was 1,460 beds (76%) compared with 1,301 beds (71%) in Q1 FY26.

Western: Revenue grew by 28%, IP volumes grew by 17%, and ARPP grew by 10% to Rs. 1,73,128. Overall occupancy was 543 beds (58%) compared with 465 beds (52%) in Q1 FY26.

Northern: Revenue grew by 16%, IP volumes grew by 6%, and ARPP grew by 10% to Rs. 1,79,989. Overall occupancy was 895 beds (73%) compared with 847 beds (70%) in Q1 FY26.

Apollo Health and Lifestyle Limited (AHLL):

- AHLL gross revenue at Rs. 499 Crore; 15% YoY growth
- Diagnostics revenue stood at Rs. 200 Crore and Spectra revenue at Rs. 80 Crore

Apollo HealthCo:

- Offline pharmacy distribution revenue stood at ₹2,629 crore and digital platform revenue at ₹348 crore, taking overall HealthCo revenue to ₹2,977 crore, up 20% YoY. The business continued to strengthen its omnichannel pharmacy and digital healthcare platform, with 151 net new stores added during the quarter, taking the network to 7,440 stores.

- Apollo 24/7 GMV stood at ₹535 crore, up 23% YoY, while the average daily order run rate across pharmacy, diagnostics and consultations, including IP/OP referrals, stood at 70K, compared with 64K in Q1 FY26.

The business continued to see healthy performance across the hospital network, supported by growth in Inpatient volumes, ARPP and Occupancy.

EXPANSION, INNOVATION AND PARTNERSHIPS

During the Quarter, Apollo advanced its healthcare expansion and innovation agenda:

1. Apollo has launched 180 bed hospital in Sarjapur, Bangalore in Q1FY27, expanding access to healthcare.
2. Health of the Nation 2026: Apollo Hospitals' latest report maps the changing health risk profile in India, highlighting how health risks are emerging earlier, remaining hidden longer and often being missed.
3. Apollo Cancer Centers became the first in India to launch Guardant Health's Shield™ Multi-Cancer Detection Test, expanding access to advanced cancer screening.
4. Apollo Hospitals signed an MoU with the ePlane Company to explore electric air ambulances and medical delivery drones for India's emergency healthcare network.

AWARDS & ACCOLADES

Apollo Hospitals and its network of hospitals continued to receive recognition for clinical excellence, patient care, operational excellence and quality during the quarter. Key recognitions included:

1. Apollo Hospitals, Chennai received the FE Healthcare Awards 2026 recognitions for Excellence in Multispecialty Care – South and Excellence in Emergency & Critical Care – South, and the IHF Award for Hospital Operational Excellence.
2. Apollo Children's Hospital, Chennai was recognised among the World's Best Hospitals 2026 by Newsweek and Statista and received a CII award for its quality improvement initiative in paediatric epilepsy care.
3. Apollo BGS Hospitals, Mysuru received multiple FE Healthcare Awards 2026 recognitions, including Excellence in Inpatient Care & Experience and Premier Stroke Centre of Excellence - South.
4. Apollo Hospitals, Bangalore was recognised as India's first certified Comprehensive Chest Pain and Stroke Centre by the American Heart Association and American Stroke Association, respectively.
5. Apollo Hospitals across Nellore, Visakhapatnam, Ahmedabad, Kolkata and Indore received recognitions from CAHO, Six Sigma Healthcare Excellence Awards and other institutions for quality, safety, endoscopy and operational excellence.
6. Apollo hospitals across the network also received recognition for excellence in medical education, sustainability, patient-centricity and responsible use of technology.

CORPORATE SOCIAL RESPONSIBILITY

During Q1 FY 2026-27, Apollo Foundation – Total Health and Billion Hearts Beating Foundation together reached over 2.35 lakh beneficiaries through integrated healthcare, preventive health, community development and social support initiatives. Total Health reached 1,23,967 beneficiaries, including through the launch of the Rural Integrated Community Development Project in Meghalaya and the completion of a Model Anganwadi Centre in Pithapuram. Billion Hearts Beating reached 1,11,935 beneficiaries through community care, senior citizen support, health camps and emergency care training. Together, these initiatives underscore Apollo's continued commitment to improving health outcomes and building healthier, more resilient communities through sustainable interventions.

About Apollo

Apollo revolutionized healthcare when Dr. Prathap Reddy opened the first hospital in Chennai in 1983. Today, Apollo is the world's largest integrated healthcare platform with over 11,100 beds across 77 hospitals, 7,400+ pharmacies, 290+ clinics and 2,600+ diagnostic centers. It has one of the world's leading cardiac and solid organ transplant programme. Apollo continues to invest in research and innovation to bring cutting-edge technologies, equipment and treatment protocols to patients. Apollo's 1,20,000 family members are dedicated to delivering exceptional care and leaving the world better than we found it.

For further details, log onto: www.apollohospitals.com

Disclaimer

Some of the statements in this document that are not historical facts are forward-looking statements. These forward-looking statements include the company's financial and growth projections as well as statements concerning its plans, strategies, intentions and beliefs concerning its business and the markets in which it operates. These statements are based on information currently available to the company, and the company assumes no obligation to update them as circumstances change. There are risks and uncertainties that could cause actual events to differ materially from those expressed or implied. These risks include, but are not limited to, market demand, competition, market conditions, the company's ability to grow its existing businesses and develop new businesses, ability to attract and retain qualified personnel, currency fluctuations and other risks common to the industry.

Annexure B

Sr. No.	Particulars	Description
1.	Reason for change viz. appointment, ~~reappointment, resignation, removal, death or otherwise~~	M/s Deloitte Haskins & Sells LLP, Chartered Accountants (ICAI Firm Registration No. 117366W/W-100018), the current Statutory Auditor will continue to undertake the audit of the Company until the conclusion of the 46th Annual General Meeting, marking the completion of their second consecutive term of 5 years. M/s Price Waterhouse Chartered Accountants LLP, Chartered Accountants, (ICAI Firm Registration No.: 012754N/N500016), have been appointed as the Statutory Auditors of the Company from the conclusion of the 46th AGM, subject to approval of the Members.
2.	Date of appointment / ~~re-appointment~~ ~~/ cessation~~ (as applicable) and Term of Appointment /~~re-appointment~~	Based on the recommendation of the Audit Committee, the Board of Directors at its Meeting held today approved the appointment of M/s Price Waterhouse Chartered Accountants LLP, Chartered Accountants, (ICAI Firm Registration No.: 012754N/N500016), as the Statutory Auditors of the Company for a term of five years i.e. from the conclusion of the 46th Annual General Meeting until the conclusion of the 51st Annual General Meeting, subject to approval of the Members.
3.	Brief profile (in case of appointment)	M/s Price Waterhouse Chartered Accountants LLP, (the "Firm") having a Firm Registration No. 012754N/ N500016, is a firm of Chartered Accountants registered with the Institute of Chartered Accountants of India. The Firm was established in the year 1991 and was converted into a limited liability partnership in the year 2014. The registered office of the Firm is at Sucheta Bhawan, 11A Vishnu Digambar Marg, New Delhi - 110 002 and has seventeen (17) branch offices in various cities in India.

APOLLO HOSPITALS ENTERPRISE LIMITED CHENNAI

Regd. Office :
19, Bishop Gardens,
Raja Annamalaipuram,
Chennai - 600 028.

General Office :
"Ali Towers" III Floor,
#55, Greams Road,
Chennai - 600 006.

Tel : 044 - 28290956 / 3896 / 6681
Telefax : 044 - 2829 0956
Email : investor.relations@apollohospitals.com
Website : www.apollohospitals.com

Sr. No.	Particulars	Description
		The Firm is primarily engaged in providing auditing and other assurance services to its clients and is a member firm of Price Waterhouse & Affiliates, a network of firms registered with the Institute of Chartered Accountants of India having Network Registration No. NRN/E/14. Price Waterhouse & Affiliates is a network of separate, distinct and independent Indian Chartered Accountant firms, each of which is registered with the Institute of Chartered Accountants of India. The Firm has more than 120 Assurance Partners as of April 1, 2026. It has a valid peer review certificate and audits various companies listed on stock exchanges in India.
4.	Disclosure of relationships between directors (in case of appointment of a Director)	Not applicable

APOLLO HOSPITALS ENTERPRISE LIMITED CHENNAI

Annexure C

S. No.	Particulars	Details
1.	The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division or undertaking or subsidiary or associate company of the listed entity during the last financial year	The turnover of the Transferred Undertaking for the financial year ended March 31, 2026 was INR 36,097 Million, representing 14.31% of the total consolidated turnover of the Company for the financial year ended March 31, 2026. The net worth of the Transferred Undertaking for the financial year ended March 31, 2026 was INR 5,959 Million, representing 5.97% of the total consolidated net worth of the Company for the financial year ended March 31, 2026.
2.	Date on which the agreement for sale has been entered into	The board of directors of AHL has approved the execution of the business transfer agreement with ACPL ("**BTA**"), subject to approval of the shareholders of AHL. The BTA shall be executed by AHL and ACPL in due course.
3.	The expected date of completion of sale/disposal	The proposed transaction is expected to be completed by October 1, 2026, or such other date as may be mutually agreed between AHL and ACPL.
4.	Consideration received from such sale/disposal	The lump sum cash consideration for the transfer of the Transferred Undertaking shall be calculated basis the book value of the assets and liabilities of the Transferred Undertaking as on the effective date of the transfer, and shall be equivalent to its fair market value, as determined in terms of Rule 53 of the Income Tax Rules, 2026 read with the provisions of the Indian Income-tax Act, 2025. Such consideration shall be discharged in accordance with the terms of the BTA.

APOLLO HOSPITALS ENTERPRISE LIMITED CHENNAI

5.	Brief details of buyers and whether any of the buyers belong to the promoter/ promoter group/group companies. If yes, details thereof.	ACPL is a wholly owned subsidiary of AHL, which in turn is a material subsidiary of the Company.
6.	Whether the transaction would fall within related party transactions? If yes, whether the same is done at arm's length".	Yes, since ACPL is the wholly owned subsidiary of AHL. The transaction shall be undertaken on an arm's length basis.
7.	Whether the sale, lease or disposal of the undertaking is outside Scheme of Arrangement? If yes, details of the same including compliance with regulations 37A of LODR Regulations.	The proposed transaction does not form part of any scheme of arrangement, and shall be undertaken by way of the BTA executed by and between ACPL and AHL. Regulation 37A is not applicable to the proposed transaction.
8.	Additionally, in case of a slump sale, indicative additional disclosures provided for amalgamation/merger, shall be disclosed by the listed entity with respect to such slump sale.	
(a)	Area of business of the entity(ies)	AHL is engaged in the business of managing and operating the Apollo 24/7 digital platform and procurement of pharmaceutical, fast moving consumer goods and other wellness products and wholesale distribution of such products. ACPL does not undertake any business as on date. Upon the consummation of the proposed transaction, it shall undertake the business of procurement and wholesale distribution of fast-moving consumer goods, wellness and personal care products (including over-the-counter and non-prescription consumer healthcare products) and other related ancillary products categorised as fast-moving consumer goods.

(b)	Rationale for slump sale	AHL is undertaking the proposed sale of the Transferred Undertaking as a going concern on a 'slump sale basis' to segregate the business of the Transferred Undertaking into a dedicated entity, for enhancing overall group efficiency.
(c)	Brief details of change in shareholding pattern (if any) of listed entity	There shall be no change in the shareholding pattern of AHL or the Company pursuant to the proposed sale of Transferred Undertaking.

APOLLO HOSPITALS ENTERPRISE LIMITED CHENNAI

Annexure D

Sr. No	Particulars	Details
1.	Brief details of options granted	36,848 options granted to eligible employees of the Company under Apollo ESOP 2024 Each Option upon exercise would be entitled for allotment of one equity share of INR 5/- each of the Company. 9,949 RSUs granted to eligible employees of the Company under Apollo ESOP 2024 Each RSUs upon exercise would be entitled for allotment of one equity share of INR 5/- each of the Company.
2.	Whether the scheme is in terms of SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021	Yes
3.	Total number of shares covered by these options	46,798 Equity shares of face value INR 5/- each of the Company.
4.	Pricing formula / Exercise Price	Option - Rs. 5,874/- per share which is at a 20% discount to the weighted average market price calculated for the period April 2025 to March 2026 RSU – Face value of Rs. 5/- each
5.	Vesting Schedule	In terms of Apollo ESOP Plan 2024 and subject to the achievement of performance conditions as specified in grant letter, Options will vest as under:

Time period	Options vested
After 1 year from the date of the grant	Nil
After 2 years from the date of the grant	40% of the options granted
After 3 years from the date of the grant	30% of the options granted
After 4 years from the date of the grant	30% of the options granted

APOLLO HOSPITALS ENTERPRISE LIMITED CHENNAI

Regd. Office :
19, Bishop Gardens,
Raja Annamalaipuram,
Chennai - 600 028.

General Office :
"Ali Towers" III Floor,
#55, Greams Road,
Chennai - 600 006.

Tel : 044 - 28290956 / 3896 / 6681
Telefax : 044 - 2829 0956
Email : investor.relations@apollohospitals.com
Website : www.apollohospitals.com

6.	Time within which Options may be exercised	The vested Options shall be exercisable within a period of 3 years from the respective dates of vesting.
7.	Options exercised	
8.	Money realized by exercise of Options	
9.	The total number of shares arising as a result of exercise of Option	Not Applicable
10.	Options lapsed	
11.	Variation of terms of Options	
12.	Brief details of significant terms	Apollo ESOP Plan 2024 was introduced to attract, reward and retain talented and eligible employees of the Company and encourage them to align individual performance with the Company's objectives. Options granted under the Scheme shall vest on satisfaction of vesting conditions which can thereafter be exercised resulting in allotment of equity shares of the Company.
13.	Subsequent changes or cancellation or exercise of such Options	Not Applicable
14	Diluted earnings per share pursuant to issue of equity shares on exercise of Options	

Regd. Office :
19, Bishop Gardens,
Raja Annamalaipuram,
Chennai - 600 028.

General Office :
"Ali Towers" III Floor,
#55, Greams Road,
Chennai - 600 006.

Tel : 044 - 28290956 / 3896 / 6681
Telefax : 044 - 2829 0956
Email : investor.relations@apollohospitals.com
Website : www.apollohospitals.com